These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20574056)

  • 21. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder.
    McIntyre RS; Alsuwaidan M; Soczynska JK; Szpindel I; Bilkey TS; Almagor D; Woldeyohannes HO; Powell AM; Cha DS; Gallaugher LA; Kennedy SH
    Hum Psychopharmacol; 2013 Sep; 28(5):421-7. PubMed ID: 24014142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the Manchester driving behavior questionnaire.
    Biederman J; Fried R; Hammerness P; Surman C; Mehler B; Petty CR; Faraone SV; Miller C; Bourgeois M; Meller B; Godfrey KM; Baer L; Reimer B
    J Adolesc Health; 2012 Dec; 51(6):601-7. PubMed ID: 23174471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults.
    Brown TE; Brams M; Gasior M; Adeyi B; Babcock T; Dirks B; Scheckner B; Wigal T
    Curr Med Res Opin; 2011; 27 Suppl 2():23-33. PubMed ID: 21973229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years.
    López FA; Childress A; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser RA; Shepski J; Arnold V
    J Atten Disord; 2017 Jan; 21(1):52-61. PubMed ID: 23407278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.
    Waxmonsky JG; Waschbusch DA; Babinski DE; Humphrey HH; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
    CNS Drugs; 2014 Jul; 28(7):665-77. PubMed ID: 24796970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
    Ginsberg L; Katic A; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Adler LA
    Curr Med Res Opin; 2011 Jun; 27(6):1097-107. PubMed ID: 21438796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.
    Dew RE; Kollins SH
    Expert Opin Pharmacother; 2010 Dec; 11(17):2907-13. PubMed ID: 20979573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.
    Wigal SB; Raja P; Shukla A
    Expert Opin Pharmacother; 2013 Jan; 14(1):137-45. PubMed ID: 23241144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
    Wigal SB; Wong AA; Jun A; Stehli A; Steinberg-Epstein R; Lerner MA
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):149-56. PubMed ID: 22372513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.
    Kollins SH; English JS; Itchon-Ramos N; Chrisman AK; Dew R; O'Brien B; McClernon FJ
    J Atten Disord; 2014 Feb; 18(2):158-68. PubMed ID: 22508760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial.
    Lyon MR; Kapoor MP; Juneja LR
    Altern Med Rev; 2011 Dec; 16(4):348-54. PubMed ID: 22214254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurobiological basis of reinforcement-based decision making in adults with ADHD treated with lisdexamfetamine dimesylate: Preliminary findings and implications for mechanisms influencing clinical improvement.
    Newcorn JH; Ivanov I; Krone B; Li X; Duhoux S; White S; Schulz KP; Bédard AV; Pedraza J; Adler L; Blair RJ
    J Psychiatr Res; 2024 Feb; 170():19-26. PubMed ID: 38101205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Krishnan S; McGough JJ
    CNS Spectr; 2008 Jul; 13(7):614-20. PubMed ID: 18622366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.
    Brams M; Moon E; Pucci M; López FA
    Curr Med Res Opin; 2010 Aug; 26(8):1809-25. PubMed ID: 20491612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.